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This follow-up study enrolled chronic hepatitis C patients to evaluate the treatment efficacy and to 
identify post-treatment seromarkers associated with risk of hepatocellular carcinoma (HCC) among 
patients with a sustained virological response (SVR) or nonsustained virological response (NSVR). A 
total of 4639 patients who received pegylated interferon and ribavirin during 2004–2013 were followed 
until December 2014. HCC was confirmed through health examinations and data linkage with a national 
database. A total of 233 HCC cases were reported after 26,163 person-years of follow-up, indicating 
an incidence of 8.9 per 1000 person-years: 6.9 for SVR and 21.6 for NSVR per 1000 person-years. The 
associated risk of HCC in patients with SVR was 0.37 (0.22–0.63) for those without cirrhosis and 0.54 
(0.31–0.92) for those with cirrhosis compared with their respective counterparts with NSVR. Among 
patients with SVR, advanced age, male gender, cirrhosis, decreased platelet count, and increased 
aspartate aminotransferase and α-fetoprotein levels were associated with HCC (p < 0.001). The 
treatment of chronic hepatitis C patients before they developed cirrhosis showed a higher efficacy than 
did the treatment of those who had already developed cirrhosis. Patients with SVR may still have a risk 
of HCC and need to be regularly monitored.
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The World Health Organisation estimates that more than 185 million people (2.8%) have been infected with 
hepatitis C virus (HCV) globally1, and approximately 50–60% of these HCV-infected people live in the western 
Pacific and southeast Asian regions2. According to previous estimations, HCV infection accounts for more than 
25% of the worldwide hepatocellular carcinoma (HCC) occurrence3. Individuals with chronic hepatitis C infec-
tion may have an increased risk of developing end-stage liver disease and extrahepatic diseases4, 5.
In recent years, a highly effective, short treatment course of orally administered direct-acting antiviral agents 
has been approved6, 7. However, these expensive drugs are not affordable for all HCV-infected patients and for 
citizens from countries with limited healthcare resources. In many countries, pegylated interferon (Peg-IFN) 
and ribavirin remain the first-line regimen for chronic hepatitis C patients. Successful treatment is defined as a 
sustained virological response (SVR), which is the absence of viremia for 24 weeks after the cessation of treat-
ment. In Asian countries, most individuals carry the favourable IL28B genotype, resulting in a superior response 
to interferon-based therapy compared with that observed among other ethnic populations8. The duration of 
required clinical follow-up for patients who have achieved SVR is still unclear. Therefore, investigating the pre-
dictors for the development of HCC among patients who have achieved treatment-induced RNA clearance is 
critical for future clinical monitoring. The identification of HCC predictors among nonresponders and patients 
with SVR will be helpful when prioritising patients to receive intensive care.
Interferon-based treatment has been documented to reduce the risk of liver transplantation, liver failure, HCC, 
and liver-related mortality9–13. Compared with nonresponders, patients with SVR showed normalized seromark-
ers in laboratory tests14 and obvious beneficial effects14–19, with a 70% decrease in the development of end-stage 
liver disease18 and 54–75% decrease in all-cause mortality15, 16. However, most of these studies recruited highly 
selected patients with advanced fibrosis or cirrhosis13, 14, 16, 19. The treatment efficacy in noncirrhotic patients who 
are still in the early clinical stages has rarely been evaluated. Infected patients are often unaware of their infection 
and therefore do not seek clinical care and treatment because liver disease progresses slowly with few symptoms. 
Because large-scale screening has been advocated to identify patients with a high risk of HCV infection, evaluat-
ing the treatment efficacy may provide information for future cost-effective estimations.
This long-term follow-up study evaluated the treatment efficacy in patients who used the conventional 
Peg-IFN and ribavirin. Additionally, we examined clinical predictors for the risk of HCC among chronic hepatitis 
C patients who received interferon-based antiviral therapy.
Methods
We conducted a multicentre prospective study to investigate the HCC risk among chronic hepatitis C patients 
who received Peg-IFN and ribavirin. The study consisted of 4639 treatment-naive patients who received standard 
care in six medical centres located in northern, middle, and southern Taiwan during 2004–2014. All participants 
were aged 30 years or older; seropositive for HCV antibodies, with detectable HCV RNA; seronegative for hepati-
tis B surface antigen; seronegative for human immunodeficiency virus; and free of HCC at enrolment and during 
treatment. The patients included in this study were provided with appropriate and complete clinical information 
regarding the treatment regimen and duration. All the study participants provided informed consent. The study 
was conducted in accordance with the ethical principles stated in the Declaration of Helsinki and was approved by 
the Ethics Committee of the National Taiwan University Hospital, Kaohsiung Medical University Hospital, China 
Medical University Hospital, Chang Gung Memorial Hospital in Kaohsiung and Linkou, and Academia Sinica.
The patients infected with HCV genotype 1 or genotype non-1 received a combination of Peg-IFN and riba-
virin therapy for 48 and 24 weeks, respectively. Serum HCV RNA test results at treatment initiation, end of 
treatment, and 24 weeks after the end of treatment were recorded. SVR was determined from the serum HCV 
RNA test results at 24 weeks after the end of treatment. Data regarding patient demographics (sex and birthdate), 
antiviral treatment (type of medication, treatment duration, and virological response), and presence of liver cir-
rhosis (ultrasonography or histological findings) were obtained. Virological data (HCV RNA levels and HCV 
genotype) and clinical laboratory findings, such as platelet count (109/L) and haemoglobin (g/dL), aspartate ami-
notransferase [AST] (U/L), alanine aminotransferase [ALT] (U/L), and α-fetoprotein (ng/mL) levels, at baseline 
and 24 weeks after the end of treatment were recorded. The fibrosis-4 score (FIB-4) was used as a surrogate to 
estimate the amount of scarring in the liver, and it was calculated from the patients’ age, serum ALT (U/L) and 
AST (U/L) levels, and platelet count (109/L)20. All clinical parameters were measured through standard laboratory 
techniques. Serum HCV RNA was measured by a commercialized sensitive assay with polymerase chain reaction 
using the COBAS TaqMan HCV test, v2.0 (Roche Diagnostics, Indianapolis, NJ, USA).
Ascertainment of HCC. At enrolment, none of the participants in this treatment cohort had been diagnosed 
with HCC. In this cohort, the patients received regular health examinations and monitoring during and after the 
end of antiviral treatment. The medical record verification of incident HCC diagnoses was based on the following 
criteria: histological examinations and the detection of a positive lesion through at least two different imaging 
techniques (abdominal ultrasonography, angiography, or computed tomography) or through one imaging tech-
nique accompanied with an elevated serum α-fetoprotein level of ≥400 ng/mL21. In addition to active follow-up, 
newly developed HCC cases from January 1, 2004 to December 31, 2014 were detected through computerised 
linkage with the profiles from the National Cancer Registration in Taiwan via matching of the participants’ iden-
tification number and birthdate. To ensure complete ascertainment, a linkage with the national death certification 
database was also performed to identify cases of HCC death. The ascertainment of newly developed HCC was 
complete and accurate4.
Statistical Analysis. The baseline characteristic profiles of patients with SVR or non-sustained virological 
response (NSVR) at the time of treatment initiation were compared using chi-squared tests. In this prospec-
tive study, we estimated the incidence of HCC from treatment responses. For each patient, the person-years 
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of follow-up were calculated from the date of treatment initiation to either the date of HCC identification, the 
date of death, or December 31, 2014, whichever came first. The incidence rates of HCC per 1,000 person-years 
were calculated by dividing the number of newly developed HCC cases by person-years of follow-up. Kaplan–
Meier method curves were used to depict cumulative risks for HCC according to SVR or NSVR throughout the 
follow-up years, and these data were compared with log-rank tests.
The treatment efficacy was evaluated by comparing the incidence of HCC between patients with SVR 
or NSVR. Cox proportional hazards models were used to examine the magnitude of HCC risk reduction in 
patients with SVR. Several clinical predictors at treatment initiation, including liver cirrhosis, platelet count lev-
els, α-fetoprotein levels, and haemoglobin concentration, were considered in multivariate models. Hazard ratios 
(HRs) with 95% confidence intervals (CIs) were used to assess the magnitude of the associations between risk 
predictors and HCC. Statistical significance levels were determined by a two-sided p value of 0.05. The pro-
portionality assumption of Cox models was examined, and the assumption was not violated. To evaluate the 
relevant predictors associated with HCC risk after treatment, additional Cox’s proportional hazards models were 
performed by stratifying patients according to their SVR status. The clinical predictors identified at the time of 
determining the SVR status were used for subsequent analyses.
The dose–response relationship between platelet count and α-fetoprotein levels and the risk of HCC, after 
adjustment for other risk predictors, were examined for statistical significance, with a test for trends. All analyses 
were performed using the SAS statistical software package (version 9.1; SAS Institute Inc., Cary, NC, USA).
Results
Baseline characteristics of SVR and NSVR patients. The clinical profiles of the 4639 patients at the 
initiation of antiviral treatment are shown in Table 1. A total of 3939 (85%) patients achieved SVR and 700 (15%) 
did not achieve SVR. Patients who achieved SVR tended to possess the following characteristics: younger age, 
male sex, HCV genotype non-1 infection, low HCV RNA levels at treatment, absence of cirrhosis, platelet count 
≥100 103/μL, low α-fetoprotein levels, and lower proportions of fibrosis (FIB-4 ≥3.25; p < 0.05).
Incidence of HCC with SVR and NSVR. A total of 233 incident HCC cases were identified after a total 
of 26,163 person-years of follow-up, and the incidence of HCC was 8.9 per 1000 person-years. Table 2 shows the 
incident HCC cases, the observed person-years, and the rate of HCC per 1000 person-years, stratified according 
to the patients’ SVR status. Of the 3939 patients with SVR, 155 developed HCC after 22,548 person-years of 
follow-up, indicating an incidence rate of 6.9 per 1000 person-years. In addition, of 700 patients with NSVR, 78 
developed HCC, indicating an incidence rate of HCC was 21.6 per 1000 person-years. Among both SVR and 
NSVR patients, those with liver cirrhosis at study entry had a higher HCC incidence than did those without liver 
cirrhosis (p < 0.01).
Determinants
Total (N = 4639)  
N (%)
NSVR (N = 700)  
N (%)
SVR (N = 3939)  
N (%) p-value
Age
 mean ± SD 53.8 ± 10.0 56.1 ± 9.4 53.4 ± 10.0 <0.0001
Gender
 Female 2304 (49.7) 393 (56.1) 1911 (48.5) 0.0002
 Male 2335 (50.3) 307 (43.9) 2028 (51.5)
HCV genotype*
 Non-1 2108 (45.4) 132 (18.9) 1976 (50.2) <0.0001
 1 2531 (54.6) 568 (81.1) 1963 (49.8)
Log HCV RNA (IU/mL)
 mean ± SD 5.7 ± 1.1 6.2 ± 0.8 5.7 ± 1.1 <0.0001
ALT (U/L)
 mean ± SD 131 ± 106.5 112.1 ± 74.4 134.3 ± 110.9 <0.0001
AST (U/L)
 mean ± SD 89.6 ± 64.1 87.1 ± 56.0 90 ± 65.4 0.2302
Hemoglobulin (g/dl)
 mean ± SD 14.2 ± 1.5 14.1 ± 1.5 14.3 ± 1.5 0.0105
Platelet count (103/uL)
 mean ± SD 173.3 ± 61.9 164.4 ± 81.8 174.8 ± 57.8 0.0031
AFP (ng/mL)
 mean ± SD 15 ± 45.3 21.8 ± 43.9 13.9 ± 45.4 0.0002
 FIB-4 ≥ 3.25 1279 (31.1) 233 (40.0) 1046 (29.7) <0.0001
 Cirrhosis 796 (17.3) 201 (28.9) 595 (15.3) <0.0001
Table 1. Baseline characteristics of study participants. HCV: hepatitis C virus; ALT: alanine aminotransferase; 
AST: aspartate aminotransferase; FIB-4: fibrosis-4 score; AFP: α-fetoprotein; SVR: sustained virological 
response; NSVR: non-sustained virological response.
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Cumulative risk of HCC with SVR and NSVR. The mean years of follow-up for the study patients was 5.6 
years. The cumulative risk of HCC was 7.6% and 24.5% in patients with SVR and NSVR, respectively (p < 0.01; 
Fig. 1A). Patients with SVR had a decreased risk of HCC, irrespective of whether they had cirrhosis at study entry 
(p < 0.01). After follow-up, the cumulative risk of HCC was 20.1% for SVR and 45.6% for NSVR among cirrhotic 
patients and 5.1% for SVR and 15.5% for NSVR among non-cirrhotic patients.
Treatment efficacy stratified by cirrhosis status at study entry. Among the non-cirrhotic patients, 
patients with SVR had a crude HR of 0.34 (0.20–0.57, p < 0.01) for HCC compared with those with NSVR, sug-
gesting a treatment efficacy of 66%. Among patients with cirrhosis at study entry, the efficacy was 48%. These 
findings suggested that treating patients before they developed cirrhosis led to higher treatment efficacy.
Pre-treatment seromarkers associated with HCC. Table 3 shows the relative risk of HCC, stratified 
by treatment response and other clinical predictors. In the univariate analysis, the development of HCC was 
associated with older age, elevated serum levels of AST and α-fetoprotein, low platelet count and haemoglobin 
levels, increased FIB-4, and the presence of liver cirrhosis (p < 0.01). After adjustment for the clinical predictors 
significantly associated with HCC at study entry, the adjusted HR (95% CI) was 0.44 (0.30–0.64) for patients 
with SVR compared with those with NSVR (p < 0.01). The associated risk of HCC in patients with SVR was 0.37 
(0.22–0.63) for those without cirrhosis and 0.54 (0.31–0.92) for those with cirrhosis compared with their respec-
tive counterparts with NSVR.
Changes in seromarkers before and after treatment. A comparison of the seromarker levels before 
and after treatment showed significantly decreased (all p < 0.001) serum levels of ALT (mean ± SD = 131.0 ± 106.6 
vs. 31.4 ± 34.1), AST (89.7 ± 64.2 vs. 31.9 ± 24.1), and α-fetoprotein (15.2 ± 46.4 vs. 5.4 ± 12.9). A total of 31.4% 
participants had FIB4 ≥ 3.25 before treatment, whereas 15.2% had FIB4 ≥ 3.25 after treatment (p < 0.001).
Post-treatment seromarkers associated with HCC. The clinical predictors at 6 months after treat-
ment cessation and the associated risk of HCC are described in Table 4. Among patients who achieved SVR, 
advanced age, male sex, elevated post-treatment AST levels, cirrhosis, decreased post-treatment platelet count, 
and increased post-treatment α-fetoprotein levels were significantly associated with HCC (p < 0.05). Moreover, 
advanced age, elevated post-treatment AST levels, and low post-treatment platelet count increased the risk of 
HCC among patients with NSVR (p < 0.05).
Discussion
In Taiwan, a national viral hepatitis treatment programme was launched since October 2003. The government 
started reimbursing patients with chronic hepatitis B or hepatitis C for antiviral therapy. The incidence and mor-
tality of end-stage liver diseases continually decreased in all age and sex groups from 2000–2003 (before the 
treatment programme) through 2004–2007 to 2008–2011. Using 2000–2003 as a reference, the incidence and 
mortality of HCC were decreased by at least 14–24%22. The availability of large national claims data and long-term 
follow-up enabled researchers to evaluate relatively rare outcomes such as HCC with sufficient power. This data-
base has been utilised to evaluate the antiviral treatment efficacy, with results showing that patients who had 
received antiviral treatment had a decreased risk of liver-related disease incidence or mortality22, 23. However, the 
SVR status of the treated patients and the predictors for the development of HCC were difficult to assess because 
of the lack of individualised data regarding clinical markers. Our study enrolled a large number of patients with 
long-term follow-up and collected detailed clinical information, which helped to identify relevant seromarkers 
that could be useful for monitoring patients after treatment.
Although the nationwide Veterans Affairs HCV Clinical Case Registry contains health information for 
all-known HCV-infected patients and collects laboratory test as well as pharmacy data in a large cohort to exam-
ine SVR efficacy and liver-related diseases after considering for potentials confounders, this population was 
overwhelmingly male; thus, the results may not apply to populations with large proportions of females15, 24. The 
epidemiological characteristics of HCV infection and treatment responses in western and eastern countries were 
different; thus, a large follow-up study to estimate the treatment efficacy is warranted before the widespread 







Rate per 1000 
person-year
Total 4639 233 26162.84 8.91
SVR 3939 155 22548.39 6.87
 -LC 595 77 3460.95 22.25
-non-LC 3304 78 18822.74 4.14
NSVR 700 78 3614.44 21.58
 -LC 201 51 1030.69 49.48
 -non-LC 494 27 2557.23 10.56
Table 2. Incidence of HCC, stratified by treatment response and presence of liver cirrhosis at study entry. HCC: 
hepatocellular carcinoma; SVR: sustained virological response; NSVR: non-sustained virological response; LC: 
liver cirrhosis; non-LC: non-liver cirrhosis *40 SVR patients and 5 NSVR patients lack of cirrhosis information
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that HCC may still occur among those with SVR, at an incidence of 3.3 per 1000 person-years24. Although our 
cohort had more female patients, the estimated incidence of HCC was 6.9 per 1000 person-years, which was still 
higher than that among the veterans. In the veteran cohort, 64% of the participants were white, and that study 
revealed ethnic differences in the occurrence of HCC, with Asians having an approximately three-fold higher 
risk of developing HCC than do whites24. Hepatitis B virus infection is endemic to Taiwan and other Asian coun-
tries. In our study, all participants showed seronegativity for the hepatitis B surface antigen. Although we did 
not test antibodies against the hepatitis B core antigen, most patients who had ever been infected by hepatitis B 
Figure 1. Cumulative risk of HCC after long-term follow-up. (a)Total participants. (b)Patients with liver 
cirrhosis at study entry. (c)Patients without liver cirrhosis at study entry.
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virus were presumably in their early childhood. Recent meta-analysis demonstrated that the risk of HCC among 
anti-HCV-seropositives was significantly higher among the subject positive for anti-HBc than the subjects nega-
tive for anti-HBc26. The risk of anti-HBc-positivity on HCC occurrence remained even after successful antiviral 
therapy27.
Patients with SVR still had a substantially increased risk of developing HCC. This study emphasised the impor-
tance of monitoring, even for patients that had treatment-induced RNA clearance28 and particularly for those 
with fibrosis (low platelet count) and elevated serum α-fetoprotein levels. Patients without SVR had increased risk 
for HCC. Thus it will be essential to intensively monitor the patients who were failed for interferon-based regimen 
and allocate them with direct-acting antivirals.
This long-term follow-up study suggested that among patients with SVR, elevated serum α-fetoprotein lev-
els after antiviral treatment were significantly associated with HCC risk in a dose–response-dependent manner. 
Serum α-fetoprotein levels are frequently used as a biomarker for HCC, but their performance was not satisfac-
tory. When 20 ng/mL was used as the cutoff value for HCC detection, the sensitivity was 41–65% and specificity 
was 80–94%29. Patients with chronic viral hepatitis and cirrhosis in the absence of HCC may still have elevated 





Patients with liver 
cirrhosis Adjusted HR 
(95% CI)
Patients without liver 
cirrhosis Adjusted HR 
(95% CI)
Age 1.05 (1.03–1.08) 1.04 (1.01–1.07) 1.07 (1.04–1.10)
Gender
 Female 1.00 1.00 1.00
 Male 2.51 (1.72–3.68) 2.78 (1.62–4.77) 1.86 (1.17–2.98)
Serum levels of AST (U/L)
 <45 1.00 1.00 1.00
 45–89 0.81 (0.43–1.51) 0.88 (0.25–3.13) 0.85 (0.42–1.74)
 ≥90 1.13 (0.61–2.12) 1.48 (0.43–5.06) 0.99 (0.47–2.10)
 p for trend 0.2324 0.1112 0.8453
Cirrhosis
 No 1.00 — —
 Yes 2.77 (1.93–3.99)
Platelet count (103/uL)
 ≥200 1.00 1.00 1.00
 100–200 1.54 (0.89–2.66) 1.20 (0.49–2.94) 1.81 (0.91–3.62)
 <100 2.32 (1.25–4.32) 1.73 (0.71–4.27) 3.41 (1.40–8.30)
 p for trend 0.0055 0.1189 0.0073
Alpha fetoprotein (ng/mL)
 <5 1.00 1.00 1.00
 5–10 2.27 (1.35–3.82) 1.68 (0.65–4.32) 2.37 (1.27–4.43)
 ≥10 2.32 (1.35–3.99) 1.97 (0.80–4.90) 2.21 (1.11–4.41)
 p for trend 0.0057 0.1523 0.0301
Hemoglobulin (g/dl)
 <13.6 1.00 1.00
 13.6–14.9 0.68 (0.46–1.01) 0.50 (0.28–0.89)
 ≥14.9 0.41 (0.25–0.68) 0.22 (0.09–0.50)
 p for trend 0.0004 <0.0001
Treatment
 NSVR 1.00 1.00 1.00
 SVR 0.44 (0.30–0.64) 0.54 (0.31–0.92) 0.37 (0.22–0.63)
Table 3. Adjusted hazard ratios and 95% confidence intervals of pretreatment predictors for HCC, stratified by 
presence of liver cirrhosis at study entry. AST: aspartate aminotransferase; SVR: sustained virological response; 
NSVR: non-sustained virological response.
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may increase the serum α-fetoprotein levels even in patients without HCC31, 32. Elevated serum α-fetoprotein lev-
els were associated with a decreased platelet count and an increased ALT-to-AST ratio33. The findings of our study 
were consistent with those of a Japanese cohort study, which showed that post-treatment serum α-fetoprotein 
levels achieved 80% predictability in detecting HCC by setting the cutoff value at 6 ng/mL34. Similarly, a recent 
study revealed that patients with α-fetoprotein levels higher than 10 ng/mL had an approximately 7.8-fold higher 
risk of developing HCC after achieving SVR35.
Regardless of the SVR status among patients, the discovery of biomarkers that may increase the predictive 
ability to identify patients with a high risk of developing HCC remains crucial. A prospective study in Japan 
found a unique fibrosis-related glycomarker that may predict the development of HCC with sufficient diagnostic 
accuracy36. Serum gamma-glutamyl transferase levels, a surrogate of oxidative stress, were associated with a sub-
sequent HCC risk among noncirrhotic patients after HCV eradication37. These seromarkers were not routinely 
used in clinical settings but could be viewed as potential biomarkers for HCC surveillance. Both positive and 
negative predictive values of these biomarkers in conjunction with abdominal ultrasonography for liver surveil-
lance should be evaluated. In the future, large-scale follow-up studies will facilitate the discovery of more useful 
biomarkers for end-stage liver disease.
HCV 1b and 2a were the predominant HCV genotypes in Taiwan. Previous studies have shown that patients 
with genotype 1 had an SVR rate of 70–80%38–40, whereas genotype 2 had an SVR rate of 74–90%41, 42. Compared 
with SVR rate in Western countries, the high SVR rate in Taiwan was due to a higher proportion of HCV geno-
type non-1 (40–45%) in Taiwan and a very high proportion of favorable IL28B genotype distribution (more than 
90%) in Taiwanese HCV patients. Approximately 80–90% of East Asian people carried the favourable IL28B 
genotype, and the polymorphisms contributed to the treatment-induced RNA clearance and RNA spontaneous 
clearance8, 43–45.
In addition to hepatic diseases, chronic HCV infection was found to cause extrahepatic diseases46–48. However, 
less than 15% of chronic hepatitis C patients seek clinical care; thus, the community effectiveness of treatment is 
approximately 7–11%49, 50. Our study suggested that early intervention had higher efficacy for reducing HCC risk 
in hepatitis C patients without liver cirrhosis than in those with cirrhosis. The establishment of health policies 
for identifying asymptomatic HCV-infected patients living in the community through large-scale screening and 
recommending these patients for clinical care will be critical issues in the future. In addition, to reduce the patient 
risk of both hepatic and extrahepatic diseases, an increase in the patient accessibility to new effective drugs is 
essential. With regard to public health, the goal of primary prevention should be to promote an increased aware-
ness and knowledge of hepatitis C through effective health education.
Predictors









Age 1.08 (1.05–1.11) 1.1 (1.06–1.14) 1.07 (1.02–1.13) 1.06 (1.00–1.13)
Gender
 Female 1.00 1.00 1.00 1.00
 Male 1.63 (1.03–2.58) 1.91 (1.04–3.51) 1.36 (0.61–3.03) 0.91 (0.29–2.83)
Serum levels of ALT (U/L)
 <45 1.00 1.00
 ≥45 0.97 (0.45–2.1) 1.52 (0.52–4.47)
Serum levels of AST (U/L)
 <45 1.00 1.00 1.00 1.00
 ≥45 2.47 (1.23–4.98) 1.79 (0.57–5.6) 6.20 (1.78–21.53) 4.11 (1.11–15.17)
Cirrhosis
 No 1.00 — 1.00
 Yes 2.14 (1.30–3.53) — 1.01 (0.42–2.44)
Platelet count (103/uL)
 ≥200 1.00 1.00 1.00
 100–200 1.30 (0.68–2.49) 1.54 (0.70–3.39) 1.00
 <100 2.19 (1.00–4.82) 1.92 (0.62–5.99) 5.52 (2.24–13.59)
 P for trend 0.0479 0.2225
Alpha fetoprotein (ng/mL)
 <5 1.00 1.00
 5–10 1.25 (0.72–2.15) 1.35 (0.67–2.72)
 10–20 2.42 (1.16–5.08) 4.16 (1.45–11.97)
 ≥20 9.58 (3.15–29.14) 8.54 (1.13–64.49)
 P for trend 0.0011 0.0053
Table 4. Adjusted hazard ratios and 95% confidence intervals of post-treatment predictors for HCC, stratified 
by treatment response. ALT: alanine aminotransferase; AST: aspartate aminotransferase; SVR: sustained 
virological response; NSVR: non-sustained virological response.
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In conclusion, our findings suggest that treating chronic hepatitis C patients before the development of 
advanced fibrosis may result in improved clinical efficacy for decreasing the risk of HCC. In addition, patients 
with SVR still require continuous surveillance for HCC.
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